Autolus Therapeutics (NASDAQ:AUTL) Stock Rating Reaffirmed by William Blair

Share on StockTwits

William Blair reiterated their buy rating on shares of Autolus Therapeutics (NASDAQ:AUTL) in a report released on Thursday, AnalystRatings.com reports.

A number of other brokerages have also weighed in on AUTL. Zacks Investment Research upgraded Autolus Therapeutics from a sell rating to a hold rating in a research note on Thursday, July 11th. Needham & Company LLC initiated coverage on Autolus Therapeutics in a research note on Monday, September 23rd. They issued a buy rating and a $26.00 target price for the company. HC Wainwright restated a buy rating and issued a $24.00 target price on shares of Autolus Therapeutics in a research note on Thursday, September 12th. Finally, ValuEngine upgraded Autolus Therapeutics from a hold rating to a buy rating in a research note on Thursday, August 1st. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The company presently has an average rating of Buy and an average price target of $33.33.

Shares of AUTL traded down $0.34 during mid-day trading on Thursday, hitting $12.05. The company’s stock had a trading volume of 35,700 shares, compared to its average volume of 155,734. Autolus Therapeutics has a one year low of $9.50 and a one year high of $53.24. The firm has a market capitalization of $573.69 million, a PE ratio of -8.49 and a beta of 0.67. The company has a debt-to-equity ratio of 0.09, a quick ratio of 13.12 and a current ratio of 13.12. The stock’s 50-day moving average is $12.51 and its two-hundred day moving average is $15.66.

Autolus Therapeutics (NASDAQ:AUTL) last announced its earnings results on Thursday, November 7th. The company reported ($0.61) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.87) by $0.26. The business had revenue of $0.30 million during the quarter, compared to analyst estimates of $2.00 million. Analysts expect that Autolus Therapeutics will post -3.14 EPS for the current fiscal year.

A number of hedge funds have recently made changes to their positions in the stock. Exane Derivatives acquired a new stake in Autolus Therapeutics in the second quarter worth about $50,000. Virtus ETF Advisers LLC increased its position in Autolus Therapeutics by 105.3% in the second quarter. Virtus ETF Advisers LLC now owns 17,311 shares of the company’s stock worth $279,000 after purchasing an additional 8,877 shares during the period. CWM LLC increased its position in Autolus Therapeutics by 29.3% in the second quarter. CWM LLC now owns 45,384 shares of the company’s stock worth $731,000 after purchasing an additional 10,274 shares during the period. Walleye Trading Advisors LLC acquired a new stake in Autolus Therapeutics in the second quarter worth about $168,000. Finally, Walleye Trading LLC acquired a new stake in Autolus Therapeutics in the second quarter worth about $170,000. Hedge funds and other institutional investors own 51.53% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1, a CD19-targeting programmed T cell therapy, which is in Phase I trial to reduce the risk of severe cytokine release syndrome; AUTO2, a dual-targeting programmed T cell therapy that is in Phase I/II clinical trial for the treatment of relapsed or refractory multiple myeloma; and AUTO3, a dual-targeting programmed T cell therapy, which is in Phase I/II clinical trials for treating relapsed or refractory diffuse large B-cell lymphoma.

See Also: Forex

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.